Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 18/20 | 0.40 |
| ▸ | HAT1 | O14929 | 17/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815145 | 0.94 | EP300 (0.41) | EP300HAT1MEN1ALDH1A1MAPT | |
| SCHEMBL4815699 | 0.93 | PTPRC (0.39) | EP300HAT1MEN1ALDH1A1MAPT | |
| SCHEMBL4812938 | 0.91 | HAT1 (0.39) | EP300HAT1MEN1ALDH1A1MAPT | |
| SCHEMBL4815682 | 0.89 | CYP1A2 (0.41) | EP300HAT1MEN1ALDH1A1MAPT | |
| SCHEMBL4813347 | 0.88 | P2RX3 (0.38) | EP300HAT1MEN1ALDH1A1MAPT | |
| SCHEMBL4815512 | 0.88 | HAT1 (0.35) | EP300HAT1MEN1ALDH1A1MAPT | |
| SCHEMBL4811272 | 0.88 | HAT1 (0.38) | EP300HAT1MEN1ALDH1A1MAPT | |
| SCHEMBL4815132 | 0.87 | KMT2A (0.38) | EP300HAT1MEN1ALDH1A1MAPT | |
| SCHEMBL4815689 | 0.84 | HAT1 (0.36) | EP300HAT1MEN1ALDH1A1MAPT | |
| SCHEMBL4812575 | 0.83 | HAT1 (0.38) | EP300HAT1MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417063-B2 | Bicyclic heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050228000-A1 | of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228000-A1 | of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent | F12, F11, F2 | EP300 3029/4885HAT1 969/4885MEN1 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.